CATIE News - Alberta-neurologic disease linked to survival
September 22, 2010 - The brain is surrounded by a layer called the blood-brain barrier. To bypass
this protective barrier, HIV can infect cells of the immune system and hide inside these cells. As these infected cells get inside the brain, they
spew new copies of HIV, viral proteins and chemical signals that cause brain cells to become dysfunctional and in some cases die. So, while HIV
infection is commonly explained as a disease that affects the immune system, the complexity and reach of the immune system is such that
ultimately this infection affects many other organ-systems, including the nervous system.
Even in the earliest days of the AIDS pandemic, doctors quickly recognized that HIV could cause a range of neurologic
problems, perhaps the most disturbing of which is HIV-related dementia.
Today, given the widespread availability of potent anti-HIV therapy (commonly called ART or HAART) in high-income
countries, HIV-associated dementia is much less common that it was in the time before HAART. But dementia is just one of several neurologic
complications that could arise from HIV infection, and researchers in Alberta were interested in studying these complications in the
present era. The findings from their large study suggest that while HIV-related dementia is much less common because of HAART,
other neurologic issues can affect a substantial proportion of HIV-positive people. Furthermore, some neurologic disorders
seen in HIV-positive people today appear to affect their survival.
Researchers at Calgary's Southern Alberta Clinic conducted a study that monitored the health of participants between
1998 and 2009. They were particularly interested in neurologic disorders among HIV-positive people. They compared features of 404 HIV-positive people
who had also been diagnosed with a neurologic disorder to features from 1,247 other HIV-positive people who did not have neurologic disorders.
In total, 1,651 HIV-positive people were enrolled in this study. Their average profile was as follows:
- 20% females, 80% males
- age - 33 years
- the main ethno-racial distribution was as follows: 70% White, 10% Aboriginal, 10% Black
- 50% were gay or bisexual
- 23% were injection drug users
- 24% had hepatitis C virus co-infection
Over the course of the study, 25% of participants were diagnosed with a neurologic disorder. People who received
this diagnosis were more likely to have:
- sought care relatively late in the course of HIV disease, as their CD4+ counts were generally lower (111 cells)
than people without neurologic disease who sought care (208 cells). And, not surprisingly, people with low CD4+ counts who were diagnosed with
neurologic disorders also were more likely to have a greater rate of AIDS-related illnesses.
- relatively higher viral loads (25,000 copies/ml) than people who did not have neurologic disorders (15,000
The following factors did not have any relationship to the development of a neurologic disorder:
- substance use
- hepatitis C virus co-infection
Focus on neurologic diagnoses
At the time neurologic disease was diagnosed, participants had been living with HIV for an average of six years.
During the study period, 53 neurologic disorders were found, the most common being the following:
- peripheral neuropathy
- HIV-associated neurocognitive disorders (HAND; this term encompasses dementia as well as minor neurocognitive
- very severe headaches
- brain infections
- problems controlling and coordinating muscles and movement
- muscle weakness
Key findings were as follows:
- People who had AIDS were between two and three times more likely to be diagnosed with a neurologic disorder
compared to people who were HIV positive but did not have AIDS.
- About 50% of people with a diagnosis of one neurologic disorder were also diagnosed with at least one other
Trends in time
Over time, the number of neurologic diagnoses decreased. For instance, between 1998 and 1999, 86 diagnoses were
made. In 2006 to 2007, only 65 new cases of neurologic disorders were diagnosed. However, because of the sizeable, though decreasing, number of
neurologic diagnoses made each year, over time the number of HIV-positive people coping with these problems rose, reaching a steady level in 2004.
Who is at greatest risk?
The people who were at greatest risk for neurologic disease were called "late presenters" by the researchers.
These are HIV-positive people who, for whatever reason(s), seek care relatively late in the course of their illness. In the present study,
late presenters often sought care when their CD4+ counts had plunged below the 200-cell mark. On average, late presenters developed
neurologic disorders an average of three years after a diagnosis of HIV infection.
The researchers also found that people whose viral loads were more than 10,000 copies/ml were at significantly
increased risk for developing HIV-associated neurocognitive disorders.
According to the researchers, to put their overall findings in perspective, neurocognitive problems occurred
at a rate that would be seen in HIV-negative people about 20 years older than people in the current study; that is, in people who were about
55 to 60 years old. This finding supports a concept that seems to be increasingly common-that HIV infection is associated with an apparent
accelerated aging of organ-systems, particularly the cardiovascular system and brain.
The good news is that rates of HIV-related neurocognitive disorders fell during the latter five years of
the study. This suggests that the increased effectiveness of HAART was able to help reduce the appearance of this troublesome complication.
Causes of death
Over the course of the study, 171 people died. People diagnosed with a neurologic disorder were at significantly
increased risk for death. Causes of death in this study were divided into three common groups as follows:
- AIDS-related deaths - 79 people
- non-AIDS-related deaths - 81 people
- unknown causes - 11 people
Having a diagnosis of HIV-associated neurocognitive disorder increased the risk of subsequent death by 300%.
Having a diagnosis of a life-threatening infection of the brain/spinal cord increased the risk of death by 500%.
Having a diagnosis of peripheral neuropathy did not increase the risk of death.
Comparing death rates
In the present study, the annual rate of death in those with and without neurologic disorders was expressed this
way by researchers:
- 18 deaths per 1,000 HIV-positive people with a neurologic disorder
- 8 deaths per 1,000 HIV-positive people without a neurologic disorder
In comparison, the annual rate of death of HIV-negative people of similar age and gender in Canada was as follows:
- 2 deaths per 1,000 people
These estimates are sobering and suggest that HIV-positive people who have a neurologic disorder may need more
frequent monitoring and/or other interventions to help prolong their survival.
An important study
The rates of HIV-associated neurocognitive problems and life-threatening infections of the brain reported in
the Alberta study were similar to those seen in large studies in the United States and the European Union. So it is likely that the Alberta
findings and their implications are robust. Other studies are now needed to assess the impact of the burden of neurocognitive disorders
in other countries to confirm and extend the results reported from this large Canadian clinic.
The results from the Alberta study underscore the need to begin monitoring and treating HIV disease long before
the CD4+ count falls to dangerous levels. This is because the damage to a weakened immune system wrought by HIV may have unexpected and
far-reaching consequences for the brain and overall health, long after HAART is initiated.
-Sean R. Hosein
- Kraft-Terry SD, Buch SJ, Fox HS, et al. A coat of many
colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron . 2009 Oct 15;64(1):133-45.
- Smith EM. Neuropeptides as signal molecules
in common with leukocytes and the hypothalamic-pituitary-adrenal axis. Brain, Behavior, and Immunity . 2008 Jan;22(1):3-14
- Snider WD, Simpson DM, Nielsen S, et al. Neurological complications of acquired immune deficiency syndrome: analysis
of 50 patients. Annals of Neurology. 1983 Oct;14(4):403-18.
- Levy JA, Shimabukuro J, Hollander H, et al. Isolation of AIDS-associated retroviruses from cerebrospinal fluid and
brain of patients with neurological symptoms. Lancet. 1985 Sep 14;2(8455):586-8.
- Carne CA, Tedder RS, Smith A, et al. Acute encephalopathy coincident with seroconversion for anti-HTLV-III. Lancet.
1985 Nov 30;2(8466):1206-8.
- Ances BM, Liang CL, Leontiev O, et al. Effects of aging on cerebral blood flow, oxygen metabolism, and blood
oxygenation level dependent responses to visual stimulation. Human Brain Mapping . 2009 Apr;30(4):1120-32.
- Ances BM, Vaida F, Yeh MJ, et al. HIV infection and aging independently affect brain function as measured by
functional magnetic resonance imaging. Journal of Infectious Diseases . 2010 Feb 1;201(3):336-40.
- Crowe SM, Westhorpe CL, Mukhamedova N, et al. The macrophage: the intersection between HIV infection and atherosclerosis.
Journal of Leukocyte Biology . 2010; Apr;87(4):589-98.
- Guaraldi G, Zona S, Alexopoulos N, et al. Coronary aging
in HIV-infected patients. Clinical Infectious Diseases . 2009 Dec 1;49(11):1756-62.
- Vivithanaporn P, Heo G, Gamble J, et al. Neurologic disease
burden in treated HIV/AIDS predicts survival. A population-based study. Neurology . 2010; in press .
CATIE-News is written by Sean Hosein, with the collaboration of other members of the Canadian AIDS Treatment
Information Exchange, in Toronto.
From Canadian AIDS Treatment Information Exchange (CATIE). For more information visit CATIE's Information
Network at http://www.catie.ca
Source: CATIE: CANADIAN AIDS TREATMENT INFORMATION EXCHANGE